Document is current
Any future updates will be listed below
-
Authors
- License Information
-
More Information
Article History
Received: 26 November 2024
Accepted: 2 December 2024
First Online: 13 December 2024
Competing interests
: LG holds research contracts with Lytix Biopharma, Promontory, and Onxeo; has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, AbbVie, OmniSEQ, Onxeo, The Longevity Labs, Inzen, Imvax, Sotio, Promontory, Noxopharm, EduCom, and the Luke Heller TECPR2 Foundation; and holds Promontory stock options. GM and IV have no conflicts of interest to declare.
